ADVANCING
NEW FRONTIERS
IN MEDICINE
Hear from Co-Founders &
Co-CEOs John Maraganore
and Clive Meanwell
Hear from Co-Founders & Co-CEOs
John Maraganore and Clive Meanwell
OUR VISION:
A WORLD WITHOUT CARDIOVASCULAR DISEASE
Corsera Health is redefining the future of health by enabling earlier prediction
of atherosclerotic cardiovascular disease (ASCVD) and developing a once-annual RNAi
medicine to prevent cumulative damage to the cardiovascular system.
Corsera Health is combining decades of innovation in RNAi therapeutics, with world-leading
expertise in cardiovascular disease prediction, efficient manufacturing and evidence generation,
and disruptive commercialization. This approach has the potential to change the trajectory of
cardiovascular disease, improving healthspan (living longer and healthier), reducing healthcare
costs, and boosting human productivity.
TEAM
Corsera Health was co-founded by industry leaders John Maraganore, Ph.D., and Clive Meanwell,
M.D., who share a vision for a world without cardiovascular disease. With a track record of
transforming cardiovascular care and establishing RNAi therapeutics as a new class of medicine,
they’ve laid the foundation for the company’s bold mission.
Corsera Health is led by a team of
accomplished experts, building on the founders’ pioneering vision to drive the next wave of
innovation in cardiovascular health.
CORSERA LEADERSHIP
John Maraganore
Co-Founder and Co-CEO
John Maraganore, Ph.D., is Co-CEO of Corsera Health.
Prior to Corsera, Dr. Maraganore served for nearly two decades as the founding CEO of Alnylam Pharmaceuticals, where he was instrumental in pioneering and advancing RNA interference (RNAi) therapeutics. Under his leadership, Alnylam secured global approvals and commercialization of the first four RNAi medicines—Onpattro®, Givlaari®, Oxlumo®, and Leqvio®. He also led the company's value creation strategy, driving its market capitalization beyond $25 billion and forging over 20 major pharmaceutical alliances. Before Alnylam, John held leadership roles at several prominent biotechnology companies, including Senior Vice President of Strategic Product Development at Millennium Pharmaceuticals, where he contributed to the development of multiple important drugs.
John received his M.S. and Ph.D. from the University of Chicago.
Clive Meanwell
Co-Founder and Co-CEO
Clive Meanwell, M.B., Ch.B., M.D. is Co-CEO of Corsera Health.
Dr. Meanwell is committed to improving population health worldwide by lowering the global burden of health from the most prevalent and costly drivers of disease and solving the disastrous disutility of existing preventative and treatment measures. With that in mind, Clive co-founded the private equity firm, Population Health Partners in 2020, where he is Executive Chairman and Managing Partner. From that platform, Clive co-founded Metsera Inc. as Chief Executive Officer and is now Executive Chairman, led creation of Areteia, Niroda, and Civia Health, and was a co-founder of Comanche Therapeutics. Clive is also a member of the Board of Directors of Fractyl Health, and Vice Chairman of the Swiss Investment Corp., BB Biotech.
Previously, Clive founded, built, and led The Medicines Company (MDCO), as Chairman, Chief Executive and Chief Innovation Officer, guiding the development of acute cardiovascular therapies—such as Angiomax® and Kengreal®—before pivoting to address the population health challenges of cardiovascular disease with the siRNA medicine, inclisiran (now Leqvio®). The Medicines Company was sold to Novartis for $9.7 billion in January 2020. Earlier in his career, Clive held senior executive leadership positions at Roche in Switzerland and the United States, contributing to the development and commercialization of numerous biopharmaceutical products. Clive received his M.B., Ch.B. and M.D. summa cum laude from the University of Birmingham, UK.
Rena Denoncourt
Chief Operating Officer
Rena Denoncourt is Chief Operating Officer at Corsera Health.
Prior to Corsera, Rena served as Vice President and TTR Franchise Global Development Lead at Alnylam Pharmaceuticals. Over her 17 years at Alnylam, Rena held positions across program management, market access, and program leadership—guiding multi-disciplinary teams from drug discovery through commercialization. She was instrumental in the approval of the first RNAi therapeutic, Onpattro®, and led the franchise's global expansion with Amvuttra®.
Rena received her MBA and B.S. from the Massachusetts Institute of Technology.
Sergio Fazio
Chief Medical Officer
Sergio Fazio, M.D., Ph.D., is Chief Medical Officer at Corsera Health.
A physician–scientist trained in internal medicine and endocrinology/metabolism, he has more than 25 years of scientific and clinical leadership in cardiometabolic disease, with deep expertise in lipid metabolism and vascular biology.
Dr. Fazio spent two decades on faculty at Vanderbilt University, where he founded and directed its lipid clinic, lipid laboratory, and cardiovascular prevention research programs. He later served for seven years as the William and Sonja Connor Chair of Preventive Cardiology at Oregon Health & Science University, building a nationally recognized preventive cardiology center and leading innovative clinical, translational, and basic research initiatives.
Before joining Corsera Health, Sergio held senior leadership roles in industry, including Chair of the Scientific Council and Vice President of Clinical Development at Regeneron Pharmaceuticals, where he guided cardio-metabolic programs and performed several novel analyses of clinical trial datasets, including PCSK9 inhibition in post-ACS patients and IL-6 receptor blockade in hospitalized COVID-19 patients.
An elected fellow of ASCI and AAP, Sergio has authored more than 300 publications and has served on numerous editorial boards and national scientific review panels. He was President of the American Board of Clinical Lipidology and founder and inaugural Editor-in-Chief of the American Journal of Preventive Cardiology.
Meredith Kaya
Chief Financial Officer
Meredith Kaya is Chief Financial Officer at Corsera Health.
Prior to Corsera, Meredith spent more than 20 years in the biotechnology industry with experience across finance, investor relations and corporate strategy, most recently as Senior Vice President of Investor Relations and Strategic Finance at Apellis Pharmaceuticals. Earlier, she served as Vice President of Finance and Investor Relations at Ironwood Pharmaceuticals, supporting multiple drug launches, a corporate separation, and financings that transformed the company into a commercial organization. Meredith began to form her career in investor relations and communications at Alnylam Pharmaceuticals.
Meredith earned a B.A. from Michigan State University and an M.B.A. from Babson College.
Jason Costigan
Head of CMC
Before joining Corsera, Jason spent nearly 18 years at Alnylam Pharmaceuticals, starting in the Oligo Synthesis lab and rising to CMC Lead for the commercial portfolio. At Alnylam, he defined strategy and oversaw execution for both early- and late-stage assets, and served as the technical representative on program leadership teams for multiple development programs. Jason’s career at Alnylam culminated as the Global CMC Lead for the commercial portfolio and he directed the technical strategy and life-cycle management of Alnylam's approved products, including Onpattro®, Amvuttra®, Givlaari®, and Oxlumo®. Earlier in his career, he held research and development roles at Ionis Pharmaceuticals and Hologic.
Jason received his B.S. in Molecular and Cell Biology from the University of Connecticut and his MA in Management with a concentration in Operations from Harvard University.
Chris Cox
Co-Founder and Legal Counsel
Chris Cox is Co-Founder and Legal Counsel at Corsera Health.
Recognized as one of the leading M&A attorneys in the United States, Chris has represented clients in over $200 billion of transactions and related financings throughout his career. Prior to Corsera, Chris co-founded Population Health Partners, where he has served as General Partner since its inception. Chris has been a corporate attorney for over 25 years, most recently a partner at Cadwalader, Wickersham & Taft LLP, where he co-chaired the global corporate group and served on the firm's management committee. Previously, Chris was Executive Vice President and Chief Corporate Development Officer at The Medicines Company.
Chris received his B.S. and J.D. from the University of Missouri.
Ashlan Musante
Head of Program & Alliance Management
Ashlan Musante is Head of Program & Alliance Management at Corsera Health.
Prior to Corsera, Ashlan spent over a decade specializing in cross-functional team leadership within the biotechnology and pharmaceutical sectors. She served as Program & Alliance Manager for Dianthus Therapeutics' lead asset, claseprubart, and contributed to the late-stage development and launch of Oxlumo® at Alnylam Pharmaceuticals—its first product approved for pediatric use. She was also a Project Management Consultant at Integrated Project Management Company, Inc.
Ashlan received her M.S. in Chemical Biology from the University of Wisconsin-Madison.
ADVISORS
Brian Ference
Co-Founder and Clinical Advisor
Brian A. Ference, M.D., is the Scientific Co-Founder of Corsera Health.
In addition to his role at Corsera, Dr. Ference is Founder and Chairman of the Deep Causal AI Institute for Clinical Translation in Cambridge, UK; and Visiting Professor of Cardiovascular Medicine at the University of Milan. He was previously Professor and Director of Research in Translational Therapeutics and Executive Director of the Centre for Naturally Randomized Trials at the University of Cambridge. Earlier, he was Chief of Cardiology and Director of the Cardiovascular Genomic Research Center at Wayne State University School of Medicine, Chief Medical and Scientific Officer working on the Chinese Precision Medicine Initiative in Beijing, and CEO of a biotechnology company. A cardiologist and quantitative genetic epidemiologist, Brian uses Mendelian randomization to design “naturally randomized trials” to discover and quantify the causes of cardiovascular disease, and use this information to accelerate drug discovery, optimize the design of randomized trials and advance the development of precision cardiovascular medicine.
Brian earned his M.D. from Yale University, completed cardiology and interventional cardiology training at Harvard Medical School, and holds additional degrees in evidence-based medicine and clinical trials from the University of Oxford and in business from the University of Cambridge.
Khurram Nasir
Chief Medical Advisor
Khurram Nasir, M.D., is Chief Medical Advisor at Corsera Health.
In addition to his role at Corsera, Dr. Nasir holds the William A. Zoghbi Centennial Chair in Cardiovascular Health at Houston Methodist, where he serves as Chief of Cardiovascular Disease Prevention & Wellness. He also co-directs the Houston Methodist–Rice Digital Health Institute, leading NIH- and PCORI-funded, AI-driven precision-prevention programs. Earlier in his career, Khurram directed cardiac imaging and genomic research at Yale, Johns Hopkins, and Massachusetts General Hospital. A preventive cardiologist and genetic epidemiologist, he has authored more than 1,000 peer-reviewed papers and ranks among the world's most-cited scientists.
Khurram earned an M.D. from the University of Punjab, an M.P.H. from Johns Hopkins, and an M.Sc. in Health Economics from the London School of Economics, and completed internal-medicine residency at Boston Medical Center and cardiology fellowship at Yale.
Hans-Peter Vornlocher
Chief Scientific Advisor
Hans-Peter Vornlocher, Ph.D., is Chief Scientific Advisor at Corsera Health.
Dr. Vornlocher is a Senior Advisor to Axolabs. Previously, Hans-Peter served as Chief Scientific Officer for Axolabs and co-founded Axolabs Kulmbach, a world-leading CRO in oligonucleotide therapeutics. Under his scientific leadership, Axolabs supported numerous pharmaceutical, biotech, and academic clients in the preclinical and clinical development of oligonucleotide therapies. Before that, Hans-Peter was Managing Director for the Roche Center of Excellence for RNA Therapeutics in Kulmbach, and served as Vice President of Research at Ribopharma and Alnylam where he directed and published groundbreaking research in RNAi therapeutics.
Hans-Peter received his Ph.D. in Biochemistry from the University of Bayreuth.
Peter Wijngaard
Co-Founder and Development Advisor
Peter Wijngaard, Ph.D., is Development Officer at Corsera Health.
Dr. Wijngaard is also a Partner at Population Health Partners, bringing with him more than 25 years of pharmaceutical industry experience. Previously, he served as Chief Development Officer at The Medicines Company, where he led the development of Leqvio® until the company's acquisition by Novartis in January 2020. Earlier in his career, he held roles in product development, medical affairs, and business development at both large and small pharmaceutical companies. Notably, Peter led the global Transplantation Life Cycle Group and was Global Alliance Director for Genentech at Hoffmann-La Roche and oversaw European Development and Medical Affairs at Viropharma.
Peter received his Ph.D. in Transplantation Immunology from Utrecht University.
CLINICAL ADVISORY BOARD
Robert A. Harrington
Robert A. Harrington, M.D. is a cardiologist and serves as the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University. His research areas of focus include evaluating antithrombotic therapies to treat acute ischemic heart disease and to minimize the acute complications of percutaneous coronary procedures and trying to better understand and improve upon the methodology of clinical research, including the use of technologies to facilitate the conduct of clinical trials.
A previous American Heart Association (AHA) president, Dr. Harrington remains a member of AHA's Board of Directors. He is also an elected member of the Association of American Physicians, the Association of University Cardiologists, and the National Academy of Medicine / Institute of Medicine. In addition, he has served as a chair and member of the US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee.
Among his numerous awards and recognition, Dr. Harrington was named a Master of the American College of Cardiology in 2016, was awarded the AHA's Clinical Research Prize in 2017, and earned the AHA Council on Clinical Cardiology (CLCD) Distinguished Achievement Award in 2022. In 2022, he was awarded the Stokes Medal, and in 2023, Honorary Fellowship in the Irish Cardiac Society. In 2024, he received the Chairman's Award and the Gold Heart Award from the AHA, as well as the Cardiovascular Research Foundation's Transcatheter Cardiovascular Therapeutics) Career Achievement Award.
Dr. Harrington earned a B.A. in English at the College of the Holy Cross and an M.D. from Tufts University School of Medicine.
John J.P. Kastelein
John J.P. Kastelein, M.D., Ph.D. is emeritus professor of medicine and Chair of the department of Vascular Medicine, and the Strategic Chair of Genetics in Cardiovascular Disease at the Academic Medical Center of the University of Amsterdam. Dr. Kastelein is a member of the Steering Committees of numerous lipid lowering and cardiovascular intervention trials. His main interest is in the development of novel therapies for cardiovascular diseases.
Dr. Kastelein was awarded a doctorate in Medicine (with Honors) from the University of Amsterdam, trained in internal medicine at the Academic Medical Center of the University of Amsterdam, and trained in lipidology and molecular biology at the University of British Columbia in Vancouver. He is a Fellow of the European Society of Cardiology (FESC). In 2010 he was awarded the prestigious Dutch Heart Association prize of EUR 1 million and in 2011 the ZonMw Parel for his research in the field of gene therapy. Dr. Kastelein published over 1500 papers in peer-reviewed Journals, his citations number over 90.000 and his Hirsch-Index is currently over 170.
Dr. Kastelein was co-founder of Xenon Pharma, Uniqure, Dezima and NewAmsterdam Pharma, where he currently holds the position of Chief Science Officer and is consultant to a number of Biotech companies in the cardiometabolic disease area.
Neha J. Pagidipati
Neha J. Pagidipati, MD, MPH, is an Associate Professor of Medicine and cardiovascular disease prevention specialist at Duke University School of Medicine and the Duke Clinical Research Institute. Since 2011, she has conducted research on CKM disease prevention, lifestyle modification, and weight management.
Dr. Pagidipati co-founded and is the director of the Duke Cardiometabolic Disease Prevention Program, which focuses on behavior change and risk factor management in patients with high risk of cardiovascular and metabolic diseases. The program's multi-disciplinary team of cardiologists, endocrinologists, nephrologists, and hepatologists work together to provide coordinated, team-based care to the most high-risk and complex patients in the health system.
Dr. Pagidipati has led key studies in the CKM space including the COORDINATE-Diabetes Trial, to improve the quality of care for patients with diabetes and cardiovascular disease across the U.S. She currently serves on the Executive Committees of multiple registration trials for lipid lowering agents, incretin therapies, and anti-hypertensive agents. She is also the contact PI for a recently awarded large NHLBI trial to optimize screening and management of younger adults with subclinical coronary atherosclerosis.
She is an Associate Editor of the Journal of the American College of Cardiology, serves on the Board of the American Society for Preventive Cardiology, and has published more than 150 peer-reviewed articles in the CKM space. She also leads prevention programming for both the ACC and AHA Scientific Sessions 2025-2026.
BOARD OF DIRECTORS
John Maraganore
John Maraganore, Ph.D., is Co-CEO of Corsera Health.
Prior to Corsera, Dr. Maraganore served for nearly two decades as the founding CEO of Alnylam Pharmaceuticals, where he was instrumental in pioneering and advancing RNA interference (RNAi) therapeutics. Under his leadership, Alnylam secured global approvals and commercialization of the first four RNAi medicines—Onpattro®, Givlaari®, Oxlumo®, and Leqvio®. He also led the company's value creation strategy, driving its market capitalization beyond $25 billion and forging over 20 major pharmaceutical alliances. Before Alnylam, John held leadership roles at several prominent biotechnology companies, including Senior Vice President of Strategic Product Development at Millennium Pharmaceuticals, where he contributed to the development of multiple important drugs.
John received his M.S. and Ph.D. from the University of Chicago.
Clive Meanwell
Clive Meanwell, M.B., Ch.B., M.D. is Co-CEO of Corsera Health.
Dr. Meanwell is committed to improving population health worldwide by lowering the global burden of health from the most prevalent and costly drivers of disease and solving the disastrous disutility of existing preventative and treatment measures. With that in mind, Clive co-founded the private equity firm, Population Health Partners in 2020, where he is Executive Chairman and Managing Partner. From that platform, Clive co-founded Metsera Inc. as Chief Executive Officer and is now Executive Chairman, led creation of Areteia, Niroda, and Civia Health, and was a co-founder of Comanche Therapeutics. Clive is also a member of the Board of Directors of Fractyl Health, and Vice Chairman of the Swiss Investment Corp., BB Biotech.
Previously, Clive founded, built, and led The Medicines Company (MDCO), as Chairman, Chief Executive and Chief Innovation Officer, guiding the development of acute cardiovascular therapies—such as Angiomax® and Kengreal®—before pivoting to address the population health challenges of cardiovascular disease with the siRNA medicine, inclisiran (now Leqvio®). The Medicines Company was sold to Novartis for $9.7 billion in January 2020. Earlier in his career, Clive held senior executive leadership positions at Roche in Switzerland and the United States, contributing to the development and commercialization of numerous biopharmaceutical products. Clive received his M.B., Ch.B. and M.D. summa cum laude from the University of Birmingham, UK.
Marco Boorsma
Marco Boorsma, Ph.D. is a Director of Corsera Health.
Dr. Boorsma is a General Partner at Forbion and has been a part of the team since 2007. Before joining Forbion, Marco was Business Development Director at DSM Pharmaceutical Products, managing biomanufacturing technologies and contract manufacturing projects, and developed manufacturing processes for biosimilars at Cytos Biotechnology.
He is especially interested in applying his experience with both small and large businesses in the fields of biotechnology, operations, and business development to the Forbion portfolio, with particular emphasis on establishing and managing new companies as part of Forbion’s build strategy.
Marco was the founding CEO of VectorY Therapeutics and was also instrumental in the launch of several biotechs, including NorthSea Therapeutics, Oxitope Pharma, Sidera, and Dezima Pharma (acquired by Amgen for up to USD 1.5 billion). He currently serves on the boards of Calluna Pharma, Orbis Medicines, Purespring Therapeutics, Rectify Pharma, Sidera Bio, Sitala, and VectorY Therapeutics.
Marco also served on the boards of Akarna (acquired by Allergan for up to USD 1 billion), Prexton Therapeutics (acquired by Lundbeck for up to USD 1.1 billion), Inflazome (acquired by Roche for USD 450 million plus contingent milestone payments), and Inversago (acquired by Novo Nordisk for up to USD 1.1 billion). Additionally, he has been a board member of Nasdaq-listed companies enGene ($ENGN), Milestone Pharmaceuticals ($MIST), and Replimune ($REPL).
Marco has an MSc in Molecular Biology from the University of Groningen and holds a PhD in Biotechnology from the ETH Institute for Technology in Zürich, Switzerland.
INVESTORS
